KEVEYIS can help patients gain greater control over Primary Periodic Paralysis (PPP). It’s proven to reduce the frequency, severity and duration of attacks.1,2
When compared with a placebo in a 9-week study1,2:
“I went from about one [attack] a week to one a month since starting KEVEYIS.”
Paul, KEVEYIS Patient and PPP Mentor
“I assumed my first call with my PAM was only for educational purposes, but after I talked to him, I realized how much better I was feeling emotionally, just being able to have contact with someone who understood what I was going through.”
Dennis, KEVEYIS patient and PPP Mentor
Hear from patients who gained greater control over PPP.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Concomitant Use of Aspirin or Other Salicylates
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.
By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.